Pegasys

Syscoin's Smart Contract Chain Is Live

Retrieved on: 
Monday, December 6, 2021
L2, Pegasys, ZKP RTVS, Xiao Luxi, AMM, Equalizer, Gold, EVM, City, TPS, Decentralized finance, Solidity, Gold standard, NFT, DEX, POW, Cryptocurrency

The best of Bitcoin & Ethereum is now together in one place.

Key Points: 
  • The Bitcoin-secured Layer 1 for EVM smart contracts reached mainnet on block 1,317,500, December 6th, 2021.
  • With this upgrade to the Syscoin network, users can simultaneously enjoy all the benefits of Bitcoin's POW security and the flexibility of smart contracts on a modular chain built to remain indefinitely decentralized, scalable, and affordable.
  • Phase One has effectively laid the world's most secure foundation for supporting all the best EVM Layer 2 advancements.
  • Syscoin's unique approach to infrastructure has addressed the greatest criticisms aimed at Bitcoin and Ethereum alike.

Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy

Retrieved on: 
Friday, December 3, 2021
Patient, National Science Board, Cornerstone, CEO, Pegasys, Safety, PD-L1, FASN, Drug, CDC classification system for HIV infection, HKEX, CHB, GBM, Hong Kong Stock Exchange, Occupational Safety and Health Act 1994, Program, Danoprevir, Disease, HCV, National Healthcare, Guideline, Gannex, Degenerative disease, National Healthcare Security Administration, FXR, Cirrhosis, Liver cancer, Hepatitis B virus, PBC, Treatment, Management process, Insurance, Phase, Acne, HIV/AIDS, Conditional sentence, Infection, R, NASH, Hepatitis C, Public health, Mortality, Ravidasvir, Hospital, NRDL, Viral hepatitis, THR, Pharmaceutical industry, Vaccine

HANGZHOU, China and SHAOXING, China, Dec. 2, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021) (《国家基本医疗保险、工伤保险和生育保险药品目录（2021）年》) (the "National Reimbursement Drug List" or the "NRDL"). 

Key Points: 
  • The results from the Phase II/III clinical trials in China with the all-oral direct anti-HCV ASCLEVIR / GANOVO regimen showed a 99% cure rate in genotype 1 non-cirrhosis HCV patients.
  • ASCLEVIR is a pan-genotypic NS5Ainhibitor with high genetic barrier to resistance, with a cure rate of 100% in patients with baseline NS5Aresistance.
  • "The assessment by National Healthcare Security Administration ("NHSA") is based on multi-factors including efficacy, safety, economy, novelty and fairness.
  • Ascletis will continue to support the country's healthcare system and contributes to the national 'Healthy China' strategy."

Ascletis Announces Approval of Phase II Clinical Trial of ASC22 (Envafolimab) by China NMPA for Immune Restoration/Functional Cure of HIV-1 Infected Patients

Retrieved on: 
Wednesday, November 10, 2021
Phase, Safety, Immunity, Hong Kong Stock Exchange, PD-L1, CDC classification system for HIV infection, HIV/AIDS, CHB, Viremia, R, Cornerstone, Hepatitis C, Hepatitis, CEO, HIV, Gannex, FXR, GBM, FASN, PD-1, HIV-1, National Medical Products Administration, PBC, OBI Pharma, Inc., NASH, Degenerative disease, Hepatitis B virus, Antibody, Cart, Infection, Acne, HKEX, THR, Patient, Death, NMPA, Pegasys, Pharmaceutical industry, Vaccine

HANGZHOU, Chinaand SHAOXING, China, Nov. 9, 2021 /PRNewswire/ --Ascletis Pharma Inc. (HKEX: 1672) today announces the approval of the Phase II clinical trial of ASC22 (Envafolimab)by China National Medical Products Administration (NMPA) for the proposed new indication of immune restoration/functional cure of human immunodeficiency virus 1 (HIV-1) infected patients.

Key Points: 
  • HANGZHOU, Chinaand SHAOXING, China, Nov. 9, 2021 /PRNewswire/ --Ascletis Pharma Inc. (HKEX: 1672) today announces the approval of the Phase II clinical trial of ASC22 (Envafolimab)by China National Medical Products Administration (NMPA) for the proposed new indication of immune restoration/functional cure of human immunodeficiency virus 1 (HIV-1) infected patients.
  • Immune restoration/functional cure in HIV-1 infected patients is the second indication of ASC22 developed by Ascletis, in addition to functional cure of chronic hepatitis B (CHB) patients.
  • (2) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.
  • Exploratory Indications: Acne: Following NASH and recurrent GBM, the third indication for ASC40 has been approved to enter Phase 2 clinical trial.

Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study

Retrieved on: 
Tuesday, November 9, 2021
Phase, Safety, Hong Kong Stock Exchange, PD-L1, American Association, Time, CDC classification system for HIV infection, HIV/AIDS, CHB, Infection, R, Cornerstone, Hepatitis C, HBsAg, CEO, IDE, Gannex, FXR, GBM, RESULTS, Society, AASLD, Nas, Institute of Liver and Biliary Sciences, Liver cancer, Immunotherapy, FASN, PD-1, Association, Liver, OBI Pharma, Inc., PBC, NASH, Degenerative disease, Hepatitis B virus, Late, American Association for Cancer Research, PLUS, Acne, HKEX, Society of Infectious Diseases Pharmacists, THR, Patient, Attention, Medicine in China, Pegasys, Medical device, Pharmaceutical industry, Vaccine

"ASC22 is the earliest and most advanced clinical stage immunotherapy in the world for CHB functional cure, i.e.

Key Points: 
  • "ASC22 is the earliest and most advanced clinical stage immunotherapy in the world for CHB functional cure, i.e.
  • Been selected for oral Late Breaking presentation indicates close attention by the committee of The Liver Meeting 2021 to the study."
  • We are excited to see ASC22 as an immunotherapy play a fundamental role in functional cure of CHB patients.
  • The percentage of patients with baseline HBsAg lower than 500 IU/mL is as high as 30% of all CHB patients.

Gannex Announces U.S. IND Approval of ASC43F, a First-in-Class Dual-Target Fixed-Dose Combination for NASH

Retrieved on: 
Monday, November 1, 2021
WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, Fibrosis, Degenerative disease, Viral disease, MD, TG, FDC, Fibroblast, Metabolic syndrome, Hong Kong Stock Exchange, Association, THR, Institute of Liver and Biliary Sciences, Tablet, FXR, NAFLD, Hepatitis B, Patient, FDA, Pegasys, Food, CHB, FGF19, PD-L1, Liver disease, HKEX, Hepatitis C, Investigational New Drug, Biomarker, TC, Cornerstone, Inflammation, Overweight, FASN, IND, R, Fatty liver disease, Serum, HIV/AIDS, NASH, American Association, Food and Drug Administration, Population, NAS, Pharmaceutical industry, Dietary supplement, Vaccine

Dr. Handan He, Chief Scientific Officer of Ascletis, stated, "NASH is a metabolic syndrome with a complex underlying pathophysiology.

Key Points: 
  • Dr. Handan He, Chief Scientific Officer of Ascletis, stated, "NASH is a metabolic syndrome with a complex underlying pathophysiology.
  • Thus, combination treatments with different mechanisms of action and/or different targets is a promising approach to combat this liver disease.
  • NASH: Gannex, a wholly-owned company of Ascletis, is dedicated to the R&D and commercialization of new drugs in the field of NASH.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.